Holen Sie sich die Stockscreener-App
0.6895
0.87%
0.00594
InspireMD Inc. Aktie (NSPR) Neueste Nachrichten
NSPR|InspireMD Inc|Price:0.694|Chg%:+0.010 - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc (NSPR) Cash Flow - TradingKey
NSPR|InspireMD Inc|Price:0.690|Chg%:+0.006 - TradingKey
InspireMD Inc. Revenue Breakdown – NASDAQ:NSPR - TradingView
InspireMD Inc. (NSPR) Q1 2026 Earnings: EPS Surpasses Estimates Despite Limited Revenue DisclosureGuidance Downgrade Alert - dars.gov.et
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD, Inc. Receives Notice of Delisting from NASDAQ – Form 8-K Filing July 2026 - Minichart
InspireMD Receives Nasdaq Minimum Bid Price Warning - Moomoo
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Receives Nasdaq Notice on Bid Price Compliance - TipRanks
InspireMD Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
InspireMD (NSPR) warned by Nasdaq over $1.00 bid price and delisting risk - Stock Titan
InspireMD gets Nasdaq notice for failing $1 minimum bid price rule - Bitget
InspireMD director Raymond W. Cohen to resign from board effective July 1, 2026 - TradingView
Board member Raymond Cohen to leave InspireMD (NSPR) effective July 1, 2026 - Stock Titan
InspireMD (NSPR) Slips 4.5% on Selling Pressure, Tests Key Support LevelPut Spread Alert - dars.gov.et
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
InspireMD, Inc.(NasdaqCM: NSPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBITDA forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to revenue forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBIT forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Price to earnings forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
InspireMD Inc. Actuals & Estimates (NASDAQ:NSPR) - TradingView
NSPR Forecast — Price Target — Prediction for 2027 - TradingView
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm - marketscreener.com
NSPR Q1 2026 Earnings: EPS Beat Surprises as Revenue Remains UndisclosedEPS Consistency Score - dars.gov.et
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc. (NSPR) Gains Momentum: Breaking Above Key SupportMarket Leader Picks - dars.gov.et
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD (NSPR) Edges Higher but Faces Test at $0.77 ResistanceRating Change - dars.gov.et
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
InspireMD reports 30-day success in trial for C... - Pluang
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
0.79%
4.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):